Bio-Techne Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TECH | 301080.SZ | 600645.SS | 002630.KS | 3759.HK | 688166.SS | |
|---|---|---|---|---|---|---|
| Market cap | 11.42B | 16.17B | 8.36B | 40.41B | 55.85B | 13.81B |
| P/E (TTM) | 62.7 | 83.1 | 74.4 | — | 27.4 | 132.1 |
| Forward P/E | 31.5 | — | 40.6 | — | 17.2 | 53.7 |
| Price/book | 5.4 | 5.9 | 2.1 | — | 2.8 | 4.5 |
| Dividend yield | 0.44% | 0.63% | — | — | 0.78% | 0.05% |
| 1-year change | +21.22% | +57.00% | −29.27% | −45.19% | +19.72% | −44.06% |
| Today | +0.10% | +1.77% | +1.94% | +13.87% | +3.47% | +2.42% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All TECH news ›Bio-Techne Releases Fourth Quarter Fiscal 2026 Results
MINNEAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2026.Fourth Quarter FY2026 HighlightsFourth quarter organic revenue increased by 3%…
Bio-Techne (TECH) CEO Kelderman gave up 2,385 shares at $72.66 to cover taxes or an exercise price
CEO Kelderman Kim had 2,385 shares withheld at $72.66 for tax on option exercise, leaving 80,509 shares held directly. Plus members following TECH got this by push and email at 16:22:09 ET - 1.1s after publication. Kim Kelderman (Chief…
Bio-Techne (TECH) CEO Kelderman acquired 21,736 shares
CEO Kim exercised 21,736 options, withheld 10,955 shares at $72.4 for tax; direct holdings now 82,894 shares, a 15% rise. Plus members following TECH got this by push and email at 16:35:44 ET - 3.4s after publication. Kim Kelderman (Chief…
Bio-Techne declares $0.08 quarterly dividend, pending Merck acquisition closure by Nov 13, 2026.
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for the period ending September 30, 2026, payable on November 23, 2026. This dividend will be paid only if the company's acquisition by Merck KGaA has not closed by…
Where Life Science Scales in Basel
The Basel region is one of the world’s leading life-science clusters. Pharmaceutical companies, biotech firms and research institutions benefit from a unique combination of talent, infrastructure and international collaboration. As the…
Organoid Culture Hydrogel Market to Surge at 16.8% CAGR by 2032 | Corning, Thermo Fisher Scientific, Bio-Techne, Merck
According to QY Research has released its latest industry focused analysis titled Global Organoid Culture Hydrogel Market Insights Industry Share Sales Projections and Demand Outlook 2026 2032 The study provides a structured perspective on…
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
Bio-Techne Corporation TECH is expected to release first-quarter fiscal 2027 results soon. The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 52 cents in the last reported quarter, matching the Zacks…
Bio-Techne opens new GMP manufacturing facility in Bristol
Bio-Techne Corporation, a global provider of life science tools, reagents and diagnostic products, today announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, further…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- tradingview.com2
- barchart.com1
- bioprocessintl.com1
- contractpharma.com1
- en.yna.co.kr1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.